Miriam O’Connor

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland

Lillian M. Smyth, G Watson, Elaine M. Walsh et al. · Breast Cancer Research and Treatment · 2015 · 34 citations

Medicine, Oncology, Pharmacoeconomics +16

Comparing attitudes of younger and older patients towards cancer clinical trials

Olubukola Ayodele, Mateen Akhtar, Aiste Konenko et al. · Journal of Geriatric Oncology · 2016 · 27 citations

Medicine, Geriatric Medicine, Oncology +7

PLACENTAL METASTASIS OF A BREAST CARCINOMA

Raymond G. Cross, Miriam O’Connor, Peter D. J. Holland · BJOG An International Journal of Obstetrics & Gynaecology · 1951 · 24 citations

Medicine, Obstetrics, Oncology +14